FXYD2 and nonpapillary renal cell carcinoma: To further investigate the FXYD2-related immune involvement in ccRCC, ssGSEA was conducted to demonstrate that decreased FXYD2 expression significantly increased enrichment of Treg, checkpoint, CCR, and APC co-inhibition.